Clinical Trials Logo

Filter by:
NCT ID: NCT05033639 Recruiting - Clinical trials for Necrotizing Enterocolitis

Efficacy Of Oral Melatonin To Prevent Necrotizing Enterocolitis

Start date: August 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Prematurity is still one of the primary causes of death in children under 5. 1-2. According to the WHO, 60% of all preterm births occur in Asia, with the Philippines accounting for around 348,900 every year. 3. Necrotizing enterocolitis is one of the fatal complications (NEC) 3, 4. Preterm newborns weighing 1500 grams or less are considered high risk. 5-6. Melatonin is one chemical that may help prevent NEC. Melatonin is an endogenous indolamine derived from serotonin. It is a ubiquitous molecule that is crucial to the body's physiologic function. Melatonin, also known as N-acetyl-5-methoxytryptamine, is an immunomodulator, antioxidant, anti-inflammatory, and free radical scavenger7-10. It is a naturally occurring chemical that is simply replenished. With this in mind, the researcher wants to see if providing high dose melatonin to premature babies can prevent NEC.

NCT ID: NCT05024006 Active, not recruiting - Covid19 Clinical Trials

Public Health Emergency: SOLIDARITY TRIAL Philippines

Start date: April 23, 2020
Phase: N/A
Study type: Interventional

This study is an adaptive, randomized, open-label, controlled clinical trial utilizing an adaptive design to compare effects of repurposed drugs with local standard of care alone on major inpatient hospital outcomes. This is performed worldwide in collaboration with WHO.

NCT ID: NCT05014373 Recruiting - Covid19 Clinical Trials

Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19

Start date: October 12, 2020
Phase: Phase 3
Study type: Interventional

This is an open label randomized controlled clinical trial which was designed to confirm the potential efficacy and safety of favipiravir in the management of patients with mild to moderate COVID-19 compared to best supportive care.

NCT ID: NCT05007821 Not yet recruiting - Tuberculosis Clinical Trials

Linezolid Dosing Strategies in Drug-Resistant TB

Start date: September 13, 2021
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy (how well the medicines work) and tolerability (whether participants stop treatment because of side effects from a drug or treatment) of an anti-TB treatment regimen that compares two doses of linezolid (LZD), combined with bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ). This study will also measure the level of these medicines in the participants' blood.

NCT ID: NCT05006573 Recruiting - Clinical trials for Non-cystic Fibrosis Bronchiectasis

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

Start date: July 21, 2021
Phase: Phase 3
Study type: Interventional

This is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, 52 week Phase III study to test the hypothesis that benralizumab will reduce exacerbation rates compared with placebo on top of standard-of-care therapy in adult patients with non-cystic fibrosis bronchiectasis with eosinophilic inflammation (NCFB+EI). All patients who complete the 52-week double-blind treatment period on investigational product (IP) may be eligible to continue into an open-label extension (OLE), during which all patients will receive benralizumab. The OLE treatment period is intended to allow patients at least one year of treatment with open label benralizumab.

NCT ID: NCT04975412 Completed - Acne Vulgaris Clinical Trials

Relationship of Whole Blood Zinc Levels to Acne Severity

Start date: November 27, 2017
Study type: Observational

Acne Vulgaris is one of the most common dermatologic diagnoses in the world. A number of studies have been conducted comparing serum zinc levels with acne vulgaris; however, no studies have yet been done in the Philippine setting. The objective of this study is to determine the relationship between whole blood zinc levels and the severity of acne vulgaris in Filipino patients and normal controls who are 18-25 years old.

NCT ID: NCT04972058 Recruiting - Ischemic Stroke Clinical Trials

Philippine Neurological Association One Database - Stroke

Start date: June 1, 2021
Study type: Observational [Patient Registry]

This is a pragmatic, multi-center, prospective, observational, non-interventional study and standing database of patients hospitalized for transient ischemic attack (TIA) or stroke in the 11 accredited adult neurology training institutions in the Philippines. Data will be collected from each patient while admitted in the hospital and until hospital discharge. Data collection for this study will span 3 years from study initiation, after which the utility of an extension or a re-implementation of the study will be assessed.

NCT ID: NCT04956367 Completed - Striae Gravidarum Clinical Trials

Efficacy of Fractional Carbon Dioxide Laser Combined With Platelet-rich Plasma

Start date: July 1, 2019
Phase: Phase 3
Study type: Interventional

This study determined the efficacy of ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma versus ablative fractional carbon dioxide laser with placebo in the treatment of striae gravidarum of postpartum Filipino women.

NCT ID: NCT04931563 Recruiting - Clinical trials for Active Systemic Lupus Erythematosus

Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)

Start date: September 13, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).

NCT ID: NCT04923958 Recruiting - Tuberculosis Clinical Trials

Rapid Research in Diagnostics Development for TB Network

R2D2TB Network
Start date: April 14, 2021
Phase: N/A
Study type: Interventional

To reduce the burden of TB worldwide through more accurate, faster, simpler, and less expensive diagnosis of TB Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) brings together experts in TB care, technology assessment, diagnostics development, laboratory medicine, epidemiology, health economics and mathematical modeling with highly experienced clinical study sites in 10 countries